| Popis: |
Ji-Hua Chen,1,2,* Zi-Han Yu,1,2,* Qin-Ling Fei Liu,1,2 Qing-Guo Meng,1,2 Xin Chen1,2 1Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, Peopleâs Republic of China; 2Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Tianjin, Peopleâs Republic of China*These authors contributed equally to this workCorrespondence: Xin Chen, Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, Peopleâs Republic of China, Email xchen03@tmu.edu.cnAbstract: With the development of economy and improvement of peopleâs living standards, the incidence of obesity and type 2 diabetes mellitus (T2DM) has increased significantly and obesity has also become one of the most important risk factors of T2DM. In light of these trends, there have been many ways to take effect in losing weight. However, they also have corresponding deficiencies including inapparent curative effect, complex and incomplete reversible procedures and severe complications. Duodenal-Jejunal Bypass Liner (DJBL), which mimics Roux-en-Y gastric bypass (RYGB), is proved to play a key role in weight loss and control of T2DM. DJBL is reversible, less invasive and is more suitable for the treatment of obesity and T2DM, which is associated with multiple mechanisms, including incretin effect, gastric emptying mechanism, bile acid regulation, intestinal microbiota, inflammatory reaction mechanism and neural mechanism. In our review, we aimed to elaborate DJBLâs clinical efficacy, safety and mechanisms in detail.Keywords: duodenal-jejunal bypass liner, obesity, type 2 diabetes mellitus, Roux-en-Y gastric bypass |
